Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Naproxen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 3/20 | 1.00 |
| ▸ | PTGS1 known ✓ | P23219 | 3/20 | 1.00 |
| ▸ | AKR1C3 | P42330 | 11/20 | 1.00 |
| ▸ | AKR1C2 | P52895 | 11/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | CDC42 | P60953 | 1/20 | 1.00 |
| ▸ | RAC1 | P63000 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.65 |
| ▸ | APP | P05067 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Naproxen SCHEMBL29360045 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL215236 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL29350675 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL28834409 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL42434 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL29359528 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL29350704 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL3046 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL10029028 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL30346195 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2011526614-A | — | — | 2011-10-13 | — | — | JP | claimed |
| US-20110172460-A1 | PROCESS FOR THE MANUFACTURE OF RACEMIC 2-ARYL-PROPIONIC ACID | AESICA PHARMACEUTICALS LIMITED (GB) | 2011-07-14 | — | — | US | claimed |
| EP-2307335-A1 | PROCESS FOR THE MANUFACTURE OF RACEMIC 2-ARYL-PROPIONIC ACID | Aesica Pharmaceuticals Ltd. (GB) | 2011-04-13 | — | — | EP | claimed |
| WO-2006099685-A1 | METHOD FOR THE PROPHYLAXIS OR TREATMENT OF CARCINOMAS | MEDICAL THERAPIES LIMITED (AU) | 2006-09-28 | — | — | WO | claimed |
| EP-0633238-A2 | Asymmetric catalytic hydrogenation of alpha-arylpropenoic acids | MONSANTO COMPANY (US) | 1995-01-11 | — | — | EP | claimed |
| US-20120041234-A1 | MICROWAVE INDUCED SINGLE STEP GREEN SYNTHESIS OF SOME NOVEL 2-ARYL ALDEHYDES AND THEIR ANALOGUES | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGISTRATION OF SOCIETIES ACT (ACT XXI OF 1860)) (IN) | 2012-02-16 | — | — | US | disclosed |
| US-20120010168-A1 | Unique Dual-Action Therapeutics | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2012-01-12 | — | — | US | disclosed |
| US-20110269689-A1 | HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS | PREMIER RESEARCH INTERNATIONAL, LLC | 2011-11-03 | — | — | US | disclosed |
| EP-2370406-A1 | HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS | Yu, Chongxi (US) | 2011-10-05 | — | — | EP | disclosed |
| US-20110172460-A1 | PROCESS FOR THE MANUFACTURE OF RACEMIC 2-ARYL-PROPIONIC ACID | AESICA PHARMACEUTICALS LIMITED (GB) | 2011-07-14 | — | — | US | disclosed |
| US-20110098284-A1 | Methods and compositions for treating pain | THERAQUEST BIOSCIENCES, LLC | 2011-04-28 | — | — | US | disclosed |
| EP-2307335-A1 | PROCESS FOR THE MANUFACTURE OF RACEMIC 2-ARYL-PROPIONIC ACID | Aesica Pharmaceuticals Ltd. (GB) | 2011-04-13 | — | — | EP | disclosed |
| US-5097064-A | By reduction of arylacrylic acid using a rhodium derivative and water soluble chiral ligand as catalyst | RHONE-POULENC SANTE (FR) | 1992-03-17 | — | — | US | disclosed |
| EP-0132690-B1 | THERMOPLASTICS CONTAINING ANTIPHLOGISTICS | Troponwerke GmbH & Co. KG (DE) | 1989-02-01 | — | — | EP | disclosed |
| EP-0201828-A2 | Components for therapeutical drug delivery devices | BAYER AG (DE) | 1986-11-20 | — | — | EP | disclosed |
| US-4623346-A | Isobutylene polymer active compound release systems | BAYER AKTIENGESELLSCHAFT (DE) | 1986-11-18 | — | — | US | disclosed |
| US-4518608-A | INDOMETHALIN WITH HYDROPHILIC COMPOUND FOR PARENTERAL ADMINISTRATION | MEDIMPEX GYOGYSZERKUELKERESKEDELMI VAALLALAT (HU) | 1985-05-21 | — | — | US | disclosed |
| US-4292319-A | MIXTURE WITH AN ANTIULCER AGENT | BOEHRINGER INGELHEIM GMBH (DE) | 1981-09-29 | — | — | US | disclosed |
| US-4256747-A | ANTIINFLAMMATORY AGENTS, PYRIDO/2,3B//1,4/BENZODIAZEPIN-6-ONES | BOEHRINGER INGELHEIM GMBH (DE) | 1981-03-17 | — | — | US | disclosed |
| US-4154833-A | INDOMETHACIN (1-(4-CHLOROBENZOYL)-5-METHOXY-2-METHYL-1H-INDOLE-3-ACETIC ACID) WITH PIRENZEPINE (5,11-DIHYDRO-11-((4-METHYL-1-PIPERAZINYL)-ACETYL)-6H-PYRIDO(2,3 -B)(1,4)BENZODIAZEPIN-6-ONE) | BOEHRINGER INGELHEIM GMBH (DE) | 1979-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172460-A1 | PROCESS FOR THE MANUFACTURE OF RACEMIC 2-ARYL-PROPIONIC ACID | SRR, GABBR2, GRHPR | PTGS2 1940/4885PTGS1 2735/4885AKR1C3 92/4885 |
| US-20120010168-A1 | Unique Dual-Action Therapeutics | ACHE, PDE1A, PDE1C | PTGS2 17/4885PTGS1 28/4885AKR1C3 217/4885 |
| US-20110269689-A1 | HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS | SLC19A1, HIRA, SLC43A1 | PTGS2 795/4885PTGS1 685/4885AKR1C3 3104/4885 |
| US-20120041234-A1 | MICROWAVE INDUCED SINGLE STEP GREEN SYNTHESIS OF SOME NOVEL 2-ARYL ALDEHYDES AND THEIR ANALOGUES | AADAC, NAT1, CTRB1 | PTGS2 34/4885PTGS1 47/4885AKR1C3 1286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.